nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.06.2006 | Original Article

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

verfasst von: E. Marcuello, A. Altés, A. Menoyo, E. Del Rio, M. Baiget

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C>T and 1298 A>C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.

Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611–1615PubMed

Danenberg PV (1977) Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73–92PubMed

Etienne MC, Llc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G (2004) Thymidylate synthase and methylenetetradydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526–534CrossRefPubMed

Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G, (2004) Pharmacogenetics 14:785–792CrossRefPubMed

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen RA (1995) Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111–113CrossRefPubMed

Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, Chan M, Rozen R (1998) Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome 9:652–656CrossRefPubMed

Gutierrez JI, Perez F, Calvo T, Tamparillas M, Gracia J (2003) Implicación de los polimorfismos C677T y A1298C del gen MTHFR en el desarrollo de los defectos del tubo neural en la población española. Med Clin (Barc) 120:441–445CrossRef

Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365–1369CrossRefPubMed

Kiffmeyer WR, Langer E, Davies S, Envall J, Robison L, Ross J (2004) Genetic polymorphisms in the Hmong population. Cancer 100:411–417CrossRefPubMed

10.

Longley DB, Harkin DP, Johnston PG, (2003) 5-Fluorouracil mechanisms of action and clinical strategies. Nat Rev Cancer 3:3330–338CrossRef

11.

Marcuello E, Altés A, Del Rio E, César A, Menoyo A, Baiget M (2004) Single nucleotide polymorphism in the 3’ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733–737CrossRefPubMed

12.

Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E, Scala I, Andria G, Botto L, and ECEMC group (2004) Frecuencia de la mutacion 677C-T del gen de la metilentetrahidrofolato reductasa en una muestra de 652 recien nacidos de toda España. Med Clin (Barc) 122:361–364CrossRef

13.

Miller SA, Dykes DD, Polesky H (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215CrossRef

14.

Sekhon J, Pereira P, Sabbaghian N, Schievella AR, Rozen R (2002) Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines. Br Jcancer 87:225–230CrossRef

15.

Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-Fluorouracil and Methotrexate. J Natl Cancer Inst 96:134–144PubMedCrossRef

16.

Stankova J, Shang J, Rozen R (2005) Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival In vitro and tumor growth in vivo. Clinical Cancer Research 11:2047–2052CrossRefPubMed

17.

Van der Put N, Gabreëls F, Stevens E, Smeitink J, Trijbels F, Eskes T, van den Heuvel L, Blom H (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051CrossRefPubMed

18.

Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, Lopez MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martinez-Frias ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD (2003) Geographical and ethnic variation of the 677C>T allele of MTHFR: findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40:619–625CrossRefPubMed

19.

World Health Organization: Handbook for Reporting Results of Cancer Treatment. Publication n° 48. Geneva, Switzerland: World Health Organization; 1979)

Titel: Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
verfasst von: E. Marcuello
A. Altés
A. Menoyo
E. Del Rio
M. Baiget
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0089-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie